In the development of therapeutic options for TNBC, Agnello et al. conjugated the anti-EGFR aptamer CL4 to (Cis-Pt)-loaded fluorescent polymeric NPs (PNPs-CL4) to achieve rapid and efficient uptake in EGFR-overexpressing MDA-MB-231 and BT-549 cells (10-fold higher uptake than the non-targeted NPs), increased toxicity (12-fold higher than the free drug), and enhanced intra-tumor accumulation in MDA-MB-231 tumor-bearing nude mice (Figure 9) [256]. The gene discussed is EGFR; the disease is neoplasm.